Is the presence of microalbuminuria a relevant marker of kidney disease?

Richard J Glassock, Richard J Glassock

Abstract

Levels of urinary albumin excretion that are below the usual limit of detection by qualitative testing, but are above normal levels (microalbuminuria; MA), can be readily identified by simple measures, such as the urinary albumin to creatinine ratio in untimed urine samples. Such measurements, particularly when combined with assessment of estimated glomerular filtration rate (eGFR), have utility as biomarkers for enhanced risk of all-cause mortality, cardiovascular events, progressive chronic kidney disease, and end-stage renal disease in diabetic and nondiabetic subjects. However, it is controversial whether "isolated" MA (MA in the absence of a clear reduction in eGFR, urine sediment abnormalities, or structural renal disease) should be regarded as kidney disease. Such MA could also be regarded as a manifestation of a diffuse endothelial (microvascular) injury and thereby collateral kidney damage. This article reviews the current evidence concerning MA as a marker of kidney disease or kidney damage.

References

    1. Svendsen PA, Oxenball B, Christiansen JS. Microalbuminuria in diabetic patients—a longitudinal study. Acta Endocrinol Suppl (Copenhagen) 1981;242:53–54.
    1. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430–1432. doi: 10.1016/S0140-6736(82)92450-3.
    1. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Clinical Practice Guidelines for Chronic Kidney Disease; Evaluation, Classification and Stratification. Am J Kidney Disease. 2002;39(Suppl 1):S1–S264.
    1. Epstein M. Aging and the kidney. J Am Soc Neprhol. 1996;7:1106–1122.
    1. Comper W, Osicka TM. Detection of urinary albumin. Adv Chronic Kidney Dis. 2005;12:170–176. doi: 10.1053/j.ackd.2005.01.012.
    1. Leong SO, Lui KF, Ng WY, Thai AC. The use of semi-quantitative urine test-strip (Micral test) for microalbuminuria screening in patients with diabetes mellitus. Singapore Med J. 1998;39:101–103.
    1. Sarafidis PA, Riehle J, Bogojevic Z, et al. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2009;28:324–329. doi: 10.1159/000111825.
    1. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88:451–487. doi: 10.1152/physrev.00055.2006.
    1. Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol. 2009;20:489–494. doi: 10.1681/ASN.2008050503.
    1. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002;39:899–919. doi: 10.1053/ajkd.2002.32764.
    1. Bundschuh I, Jackle-Meyer I, Luneberg E, et al. Glycation of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy. Eur J Chem Clin Biochem. 1992;30:651–656.
    1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375:1296–1309. doi: 10.1016/S0140-6736(09)62004-3.
    1. Hallan SI, Ritz E, Lydersen S, et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20:1069–1077. doi: 10.1681/ASN.2008070730.
    1. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Alberta Kidney Disease Network: Relation between kidney function, proteinuria and adverse outcomes. JAMA. 2010;301:423–429. doi: 10.1001/jama.2010.39.
    1. van der Velde M, de Jong PE, Gansevoort RT: Comparison of the yield of differing screening approaches to detect chronic kidney disease. Nephrol Dial Transplant 2010 (Epub ahead of print).
    1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2018–2047. doi: 10.1001/jama.298.17.2038.
    1. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081. doi: 10.1016/S0140-6736(10)60674-5.
    1. Kalaitzidis RG, Bakris GL: Serum creatinine vs albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010 (Epub ahead of print).
    1. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–2293. doi: 10.1056/NEJMoa021835.
    1. Steinke JM, Sinaiko AR, Kramer MS, et al. International Diabetic Nephropathy Study Group: The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes. 2005;54:2164–2171. doi: 10.2337/diabetes.54.7.2164.
    1. Glassock R. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010;31:462–465. doi: 10.1159/000313553.
    1. Bello AK, de Zeeuw D, El Nahas M, et al. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant. 2007;22:1619–1627. doi: 10.1093/ndt/gfm091.
    1. Vlassara H, Torreggiani M, Post JB, et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl. 2009;114:S3–S11. doi: 10.1038/ki.2009.401.
    1. Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2010;77:57–64. doi: 10.1038/ki.2009.399.
    1. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51. doi: 10.1056/NEJMoa0808400.
    1. Ito H, Takeuchi Y, Ishida H, et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant. 2010;25:1161–1167. doi: 10.1093/ndt/gfp579.
    1. Bakris GL, Sarafidis PA, Weir MR, et al. ACCOMPLISH Trial Investigators: Renal outcomes with different fixed dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised clinical trial. Lancet. 2010;375:1173–1181. doi: 10.1016/S0140-6736(09)62100-0.
    1. Lorenzo V, Saracho R, Zamora J, et al. Similar renal decline in diabetic and non-diabetic patients with comparable degrees of albuminuria. Nephrol Dial Transplant. 2010;25:835–841. doi: 10.1093/ndt/gfp475.
    1. de Jong P, Gansevoort RT. Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant. 2010;25:656–658. doi: 10.1093/ndt/gfp691.
    1. Choi SW, Yun WJ, Kim HY, et al. Association between albuminuria, carotid atherosclerosis, arterial stiffness and peripheral artery disease in Korean type 2 diabetic patients. Kidney Blood Press Res. 2010;33:111–118. doi: 10.1159/000313594.
    1. Solbu MD, Jenssen TG, Eriksen BO, Toft I. Changes in insulin sensitivity, renal function and markers of endothelial dysfunction in hypertension—the impact of microalbuminuria: a 13 year follow-up study. Metabolism. 2009;58:408–415. doi: 10.1016/j.metabol.2008.10.016.
    1. Silva AM, Schaan BD, Signori LU, et al.: Microalbuminuria is associated with impaired arterial and venous endothelium dependent vasodilation in patients with type 2 diabetes. J Endocrinol Invest 2010 (Epub ahead of print).
    1. Foster MC, Keyes MJ, Larson MG, et al. Relations of measures of endothelial function and kidney disease: the Framingham Heart Study. Am J Kidney Dis. 2008;52:859–867. doi: 10.1053/j.ajkd.2008.04.027.
    1. Rifkin DE, Katz R, Chonchoi M, et al. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant. 2010;25:1560–1567. doi: 10.1093/ndt/gfp646.
    1. Bielby J, Divitini ML, Knuiman MW, et al. Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem. 2010;56:799–804. doi: 10.1373/clinchem.2009.135962.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera